| Name | Title | Contact Details |
|---|
TransMolecular, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Raptor is a NASDAQ-listed biopharmaceutical company with the mission to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases. Raptor`s lead product, PROCYSBI (cysteamine bitartrate) delayed-release capsules, received FDA approval on April 30, 2013. The Company anticipates receiving a determination from the EMA regarding its PROCYSBI marketing application in the European Union in the second half of 2013. Raptor’s product pipeline may advance therapeutic options for additional indications. Raptor`s management team consists of repeat entrepreneurs with the experience to build a successful company.
Technologie BiolActis Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Solid Biosciences (Solid) is a Cambridge, MA based biotech company singularly focused on developing treatments and cures for Duchenne Muscular Dystrophy (DMD). Solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. Condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of DMD.
Morphic Therapeutic is leading the development of a new generation of oral integrin drugs. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders and immuno-oncology. Morphic was created in 2015 with support from Leukon Investment, Polaris Partners, Schrödinger Inc., and ShangPharma. New investors SROne, Pfizer Ventures, Omega Partners and AbbVie joined for the Series A round in June 2016.